Morgan Stanley Arcturus Therapeutics Holdings Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Morgan Stanley holds 538,494 shares of ARCT stock, worth $9.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

538,494

Previous 266,922 101.74%

Holding current value

$9.11 Million

Previous $6.2 Million 47.51%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$14.82 - $25.48 $4.02 Million - $6.92 Million	271,572 Added 101.74%	538,494 $9.14 Million
Q3 2024 Nov 14, 2024	SELL	$18.08 - $25.38 $9.56 Million - $13.4 Million	-529,019 Reduced 66.46%	266,922 $6.2 Million
Q2 2024 Oct 17, 2024	SELL	$24.35 - $44.39 $1.77 Million - $3.22 Million	-72,506 Reduced 8.35%	795,941 $19.4 Million
Q2 2024 Aug 14, 2024	SELL	$24.35 - $44.39 $1.77 Million - $3.22 Million	-72,506 Reduced 8.35%	795,941 $19.4 Million
Q1 2024 Oct 17, 2024	BUY	$31.23 - $42.99 $2.26 Million - $3.12 Million	72,506 Added 9.11%	868,447 $29.3 Million
Q1 2024 Aug 16, 2024	BUY	$31.23 - $42.99 $8.95 Million - $12.3 Million	286,450 Added 49.22%	868,447 $29.3 Million
Q1 2024 May 15, 2024	BUY	$31.23 - $42.99 $8.95 Million - $12.3 Million	286,450 Added 49.22%	868,447 $29.3 Million
Q4 2023 Aug 16, 2024	SELL	$17.71 - $32.97 $3.79 Million - $7.05 Million	-213,944 Reduced 26.88%	581,997 $18.4 Million
Q4 2023 Feb 13, 2024	BUY	$17.71 - $32.97 $148,144 - $275,794	8,365 Added 1.46%	581,997 $18.4 Million
Q3 2023 Nov 15, 2023	BUY	$25.44 - $37.35 $9.29 Million - $13.6 Million	365,215 Added 175.23%	573,632 $14.7 Million
Q2 2023 Aug 14, 2023	BUY	$23.94 - $32.36 $2.17 Million - $2.94 Million	90,842 Added 77.26%	208,417 $5.98 Million
Q1 2023 May 15, 2023	SELL	$14.72 - $23.97 $44,940 - $73,180	-3,053 Reduced 2.53%	117,575 $2.82 Million
Q4 2022 Feb 14, 2023	BUY	$14.14 - $23.06 $509,633 - $831,128	36,042 Added 42.61%	120,628 $2.05 Million
Q3 2022 Nov 14, 2022	SELL	$13.05 - $22.13 $2.97 Million - $5.04 Million	-227,625 Reduced 72.91%	84,586 $1.25 Million
Q2 2022 Oct 27, 2022	BUY	$12.26 - $31.17 $395,274 - $1 Million	32,241 Added 11.52%	312,211 $4.91 Million
Q2 2022 Aug 15, 2022	BUY	$12.26 - $31.17 $395,274 - $1 Million	32,241 Added 11.52%	312,211 $4.91 Million
Q1 2022 Oct 27, 2022	SELL	$17.64 - $39.57 $568,731 - $1.28 Million	-32,241 Reduced 10.33%	279,970 $7.55 Million
Q1 2022 May 13, 2022	BUY	$17.64 - $39.57 $2.51 Million - $5.63 Million	142,391 Added 103.5%	279,970 $7.55 Million
Q4 2021 Feb 14, 2022	BUY	$34.2 - $47.56 $136 - $190	4 Added 0.0%	137,579 $5.09 Million
Q3 2021 Nov 15, 2021	BUY	$27.88 - $58.25 $3.84 Million - $8.01 Million	137,575 New	137,575 $6.57 Million

Others Institutions Holding ARCT

# of Institutions

168

Shares Held

26M

Call Options Held

163K

Put Options Held

173K

View Full List

About Arcturus Therapeutics Holdings Inc.

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $450M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

More about ARCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account